Simon Morriss - Genetic Technologies Chief Officer
| GENE Stock | USD 0.77 0.00 0.00% |
Insider
Simon Morriss is Chief Officer of Genetic Technologies
| Age | 51 |
| Address | 321 Chapel Street, Prahran, VIC, Australia, 3181 |
| Phone | 61 3 8412 7000 |
| Web | https://genetype.com |
Genetic Technologies Management Efficiency
The company has return on total asset (ROA) of (0.6293) % which means that it has lost $0.6293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8498) %, meaning that it created substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.82. The current year's Return On Capital Employed is expected to grow to -5.83. At present, Genetic Technologies' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.6 M, whereas Non Current Assets Total are forecasted to decline to about 2.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan Rataj | Agilent Technologies | 63 | |
| John Bellano | MDxHealth SA ADR | 55 | |
| Michael McGarrity | MDxHealth SA ADR | 61 | |
| Katharine Knobil | Agilent Technologies | 56 | |
| John CPA | T2 Biosystms | 66 | |
| Robert Harrison | Sera Prognostics | 58 | |
| Brett Giffin | T2 Biosystms | 65 | |
| Miri ChikoRadomski | Precipio | N/A | |
| Nadia Altomare | Sera Prognostics | 53 | |
| John Boniface | Sera Prognostics | 62 | |
| Paul Kearney | Sera Prognostics | 56 | |
| Alex Arzeno | Intelligent Bio Solutions | N/A | |
| Paul Marr | MDxHealth SA ADR | N/A | |
| Keith Meadors | Precipio | N/A | |
| Steven Graves | Sera Prognostics | N/A | |
| Maria JD | bioAffinity Technologies, | 68 | |
| Sean MD | Sera Prognostics | N/A | |
| MBA MBA | Sera Prognostics | 70 | |
| Michael MD | Sera Prognostics | N/A | |
| Aparna MD | T2 Biosystms | 57 | |
| Michael Esq | T2 Biosystms | 53 | |
Management Performance
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 |
Genetic Technologies Leadership Team
Elected by the shareholders, the Genetic Technologies' board of directors comprises two types of representatives: Genetic Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genetic. The board's role is to monitor Genetic Technologies' management team and ensure that shareholders' interests are well served. Genetic Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genetic Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Camilleri, Chief EasyDNA | ||
| Mark Ziirsen, CFO Secretary | ||
| CPA BCom, Chief Secretary | ||
| Erika Spaeth, Director Affairs | ||
| AGIA BCom, CFO Sec | ||
| Bus FCI, Consultant | ||
| Simon Morriss, Chief Officer | ||
| Richard Allman, Scientific Director | ||
| Carl BSc, Chief Officer |
Genetic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genetic Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 3.61 M | ||||
| Shares Outstanding | 4.85 M | ||||
| Shares Owned By Institutions | 1.10 % | ||||
| Number Of Shares Shorted | 25.84 K | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 3.10 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 2.19 | Quarterly Revenue Growth (0.11) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.